title: Prevention of and medical therapy for atrial arrhythmias in heart failure.
abstract: A large proportion of heart failure patients suffer from atrial arrhythmias, prime amongst them being atrial fibrillation (AF). Ventricular dysfunction and the syndrome of heart failure can also be a concomitant pathology in up to 50% of patients with AF. However this association is more than just due to shared risk factors, research from animal and human studies suggest a causal relationship between AF and heart failure. There are numerous reports of tachycardia-induced heart failure where uncontrolled ventricular rate in AF results in heart failure, which is reversible with cardioversion to sinus rhythm or ventricular rate control. However the relationship extends beyond tachycardia-induced cardiomyopathy. Optimal treatment of AF may delay progressive ventricular dysfunction and the onset of heart failure whilst improved management of heart failure can prevent AF or improve ventricular rate control. Prevention and treatment of atrial arrhythmias, and in particular atrial fibrillation, is therefore an important aspect of the management of patients with heart failure. This review describes the incidence and possible predictors of AF and other atrial arrhythmias in patients with heart failure and discusses the feasibility of primary prevention. The evidence for the management of atrial fibrillation in heart failure is systematically reviewed and the strategies of rate versus rhythm control discussed in light of the prevailing evidence.
authors.affiliation: Department of Cardiology, Western Infirmary, Glasgow, UK. Akhand31@acl.com
authors.forename: A U
authors.initials: AU
authors.lastname: Khand
authors.forename: J G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: P C
authors.initials: PC
authors.lastname: Deedwania
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D001282:Atrial Flutter / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D004359:Drug Therapy, Combination; D004554:Electric Countershock; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010138:Pacemaker, Artificial; D010627:Phenethylamines / Q000008:administration & dosage; D011412:Propanolamines / Q000627:therapeutic use; D012985:Software Design; D013449:Sulfonamides / Q000008:administration & dosage
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002227:Carbazoles; D010627:Phenethylamines; D011412:Propanolamines; D013449:Sulfonamides; D000077261:Carvedilol; D000638:Amiodarone; C063533:dofetilide